FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048887265> ?p ?o ?g. }

• W3048887265 endingPage "106142" @default.
• W3048887265 startingPage "106142" @default.
• W3048887265 abstract "In January 2018, the European Union (EU) approved ocrelizumab in relapsing multiple sclerosis (RMS) and as the first disease-modifying therapy (DMT) for patients with primary progressive multiple sclerosis (PPMS) with efficacy proven in a phase 3 randomised controlled trial. Eleven months prior to the European regulatory approval, a compassionate use programme (CUP) made ocrelizumab available to 489 patients with PPMS in Germany, thereby for the first time providing a therapeutic option to patients with PPMS who could not participate in ocrelizumab studies. Here, we report real-world patient characteristics and short-term safety data of patients with PPMS treated with ocrelizumab in this CUP. This CUP was initiated in February 2017 – shortly before US Food and Drug administration approval in March 2017 – and ended in January 2018, following ocrelizumab approval in the EU. Adult patients (age ≥18 years) with PPMS who had a positive benefit/risk ratio according to the treating physician were eligible for inclusion at German treatment centres. The main exclusion criteria were current/recent treatment with other immune therapies and unresolved/chronic/active infections. Patients received methylprednisolone and an antihistamine before treatment with intravenous ocrelizumab in 6-month cycles. The first ocrelizumab dose was a 300 mg infusion followed by a second 300 mg infusion 2 weeks later; subsequent doses were delivered as a single 600 mg infusion. Adverse events were reported immediately. Of 580 requests received from 104 centres, 525 patients met the eligibility criteria. Thirty-five patients did not participate due to withdrawal by the treating physician, and one due to death prior to treatment. A total of 489 patients received at least one 600 mg dose of ocrelizumab (administered as two 300 mg infusions) and 51 received a second dose. Due to termination of the CUP upon marketing authorisation, the maximum follow-up period was 12 months. Median patient age was 52 years (range: 24–73), and 49% were female. Previous immunomodulatory or immunosuppressive therapies had been received by 41% of patients, with the most commonly used being glucocorticoids, mitoxantrone, interferon-β and glatiramer acetate. Patients with a previous malignancy, serious disease or infection (42 patients, 9%) had recovered from this prior to the CUP. Nine serious adverse events and 70 non-serious adverse events were reported in 40 patients. Adverse event categories were generally consistent with the known safety profile of ocrelizumab; one patient had carry-over progressive multifocal leukoencephalopathy (PML) due to previous natalizumab treatment. This CUP provides first real-world observations of ocrelizumab for the treatment of PPMS in a large patient cohort in Germany, supporting that ocrelizumab is generally well-tolerated in clinical practice. Physicians should be vigilant for early symptoms of PML, as to date, 9 PML cases that were all confounded have been reported in patients treated with ocrelizumab worldwide, with 8 carry-over cases from a prior DMT." @default.
• W3048887265 created "2020-08-18" @default.
• W3048887265 creator A5001561351 @default.
• W3048887265 creator A5003480394 @default.
• W3048887265 creator A5015293531 @default.
• W3048887265 creator A5023701418 @default.
• W3048887265 creator A5034443516 @default.
• W3048887265 creator A5038633707 @default.
• W3048887265 creator A5042488055 @default.
• W3048887265 creator A5046354840 @default.
• W3048887265 creator A5050848210 @default.
• W3048887265 creator A5057183308 @default.
• W3048887265 creator A5060874709 @default.
• W3048887265 creator A5070191933 @default.
• W3048887265 creator A5071258405 @default.
• W3048887265 creator A5084784816 @default.
• W3048887265 date "2020-10-01" @default.
• W3048887265 modified "2023-09-26" @default.
• W3048887265 title "Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany" @default.
• W3048887265 cites W1990040006 @default.
• W3048887265 cites W2053683902 @default.
• W3048887265 cites W2059920706 @default.
• W3048887265 cites W2088377755 @default.
• W3048887265 cites W2107008240 @default.
• W3048887265 cites W2122545833 @default.
• W3048887265 cites W2528753998 @default.
• W3048887265 cites W2561881161 @default.
• W3048887265 cites W2565433170 @default.
• W3048887265 cites W2614325279 @default.
• W3048887265 cites W2739632067 @default.
• W3048887265 cites W2793013701 @default.
• W3048887265 cites W2941713419 @default.
• W3048887265 doi "https://doi.org/10.1016/j.clineuro.2020.106142" @default.
• W3048887265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32920498" @default.
• W3048887265 hasPublicationYear "2020" @default.
• W3048887265 type Work @default.
• W3048887265 sameAs 3048887265 @default.
• W3048887265 citedByCount "7" @default.
• W3048887265 countsByYear W30488872652020 @default.
• W3048887265 countsByYear W30488872652021 @default.
• W3048887265 countsByYear W30488872652022 @default.
• W3048887265 countsByYear W30488872652023 @default.
• W3048887265 crossrefType "journal-article" @default.
• W3048887265 hasAuthorship W3048887265A5001561351 @default.
• W3048887265 hasAuthorship W3048887265A5003480394 @default.
• W3048887265 hasAuthorship W3048887265A5015293531 @default.
• W3048887265 hasAuthorship W3048887265A5023701418 @default.
• W3048887265 hasAuthorship W3048887265A5034443516 @default.
• W3048887265 hasAuthorship W3048887265A5038633707 @default.
• W3048887265 hasAuthorship W3048887265A5042488055 @default.
• W3048887265 hasAuthorship W3048887265A5046354840 @default.
• W3048887265 hasAuthorship W3048887265A5050848210 @default.
• W3048887265 hasAuthorship W3048887265A5057183308 @default.
• W3048887265 hasAuthorship W3048887265A5060874709 @default.
• W3048887265 hasAuthorship W3048887265A5070191933 @default.
• W3048887265 hasAuthorship W3048887265A5071258405 @default.
• W3048887265 hasAuthorship W3048887265A5084784816 @default.
• W3048887265 hasBestOaLocation W30488872651 @default.
• W3048887265 hasConcept C118552586 @default.
• W3048887265 hasConcept C126322002 @default.
• W3048887265 hasConcept C197934379 @default.
• W3048887265 hasConcept C2778843634 @default.
• W3048887265 hasConcept C2779338263 @default.
• W3048887265 hasConcept C2780640218 @default.
• W3048887265 hasConcept C2780653079 @default.
• W3048887265 hasConcept C71924100 @default.
• W3048887265 hasConceptScore W3048887265C118552586 @default.
• W3048887265 hasConceptScore W3048887265C126322002 @default.
• W3048887265 hasConceptScore W3048887265C197934379 @default.
• W3048887265 hasConceptScore W3048887265C2778843634 @default.
• W3048887265 hasConceptScore W3048887265C2779338263 @default.
• W3048887265 hasConceptScore W3048887265C2780640218 @default.
• W3048887265 hasConceptScore W3048887265C2780653079 @default.
• W3048887265 hasConceptScore W3048887265C71924100 @default.
• W3048887265 hasLocation W30488872651 @default.
• W3048887265 hasLocation W30488872652 @default.
• W3048887265 hasOpenAccess W3048887265 @default.
• W3048887265 hasPrimaryLocation W30488872651 @default.
• W3048887265 hasRelatedWork W2272446420 @default.
• W3048887265 hasRelatedWork W2617222556 @default.
• W3048887265 hasRelatedWork W2904697613 @default.
• W3048887265 hasRelatedWork W2904749964 @default.
• W3048887265 hasRelatedWork W2997394796 @default.
• W3048887265 hasRelatedWork W3034725616 @default.
• W3048887265 hasRelatedWork W3036083494 @default.
• W3048887265 hasRelatedWork W3041928636 @default.
• W3048887265 hasRelatedWork W3206414309 @default.
• W3048887265 hasRelatedWork W4306253278 @default.
• W3048887265 hasVolume "197" @default.
• W3048887265 isParatext "false" @default.
• W3048887265 isRetracted "false" @default.
• W3048887265 magId "3048887265" @default.
• W3048887265 workType "article" @default.